new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Immunomedics Inc
Immunomedics Inc_20100114
Immunomedics Inc_20100121

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Immunomedics Inc patents


      
Recent patent applications related to Immunomedics Inc. Immunomedics Inc is listed as an Agent/Assignee. Note: Immunomedics Inc may have other listings under different names/spellings. We're not affiliated with Immunomedics Inc, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunomedics Inc-related inventors




Search recent Press Releases: Immunomedics Inc-related press releases
Count Application # Date Immunomedics Inc patents (updated weekly) - BOOKMARK this page
12015020231907/23/15  new patent  Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
22015020232007/23/15  new patent  Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
32015019665307/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
42015019665407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
52015019666107/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
62015019666207/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
72015019666407/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
82015019666507/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
92015019666607/16/15 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
102015018263307/02/15 Immunoconjugates with an intracellularly-cleavable linkage
112015018388007/02/15 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
122015017426906/25/15 Immunoconjugates with an intracellularly-cleavable linkage
132015017427006/25/15 Immunoconjugates with an intracellularly-cleavable linkage
142015016507506/18/15 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
152015016507606/18/15 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
162015016665906/18/15 Humanized l243 antibodies
172015016666906/18/15 Anti-cd74 immunoconjugates and methods of use
182015015096906/04/15 Chimeric and humanized anti-histone antibodies
192015013276805/14/15 Anti-pancreatic cancer antibodies
202015012538605/07/15 Humanized anti-ceacam5 antibody and uses thereof
212015011127904/23/15 Class i anti-cea antibodies and uses thereof
222015009445604/02/15 Anthracycline-antibody conjugates for cancer therapy
232015008648203/26/15 Dye conjugated peptides for fluorescent imaging
242015005743202/26/15 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
252015003868602/05/15 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
262015001851601/15/15 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
272014037717312/25/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
282014037717712/25/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
292014037728712/25/14 Anti-trop-2 antibody-drug conjugates and uses thereof
302014036992712/18/14 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
312014028686009/25/14 Immunoconjugates with an intracellularly-cleavable linkage
322014028686109/25/14 Rs7 antibodies
332014023420908/21/14 Chimeric and humanized anti-histone antibodies
342014022717808/14/14 Humanized anti-hla-dr antibodies
352014022717908/14/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
362014022718008/14/14 Antibody-sn-38 immunoconjugates with a cl2a linker
372014022854108/14/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
382014021991408/07/14 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
392014021995608/07/14 Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
402014021242507/31/14 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
412014019335907/10/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
422014017829406/26/14 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
432014017006506/19/14 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
442014015427306/05/14 Anthracycline-antibody conjugates for cancer therapy
452014014738205/29/14 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
462014014092405/22/14 Humanized l243 antibodies
472014012003505/01/14 Rs7 antibodies
482014011286404/24/14 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
492014011286504/24/14 Anti-cd19 antibodies
502014010581904/17/14 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
512014009925804/10/14 Camptothecin-binding moiety conjugates
522014008683003/27/14 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
532014008683203/27/14 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
542014007962903/20/14 Class i anti-cea antibodies and uses thereof
552014005806702/27/14 Immunoconjugates with an intracellularly-cleavable linkage
562014004463902/13/14 Antibody therapy
572014004464002/13/14 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
582014003754302/06/14 Anti-pancreatic cancer antibodies
592014003826102/06/14 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
602014003828402/06/14 Mammalian cell lines for increasing longevity and protein yield from a cell culture
612014001716801/16/14 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
622014001719701/16/14 Anti-cd19 antibodies
632014000407801/02/14 Immunoconjugates with an intracellularly-cleavable linkage
642013031582111/28/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
652013030917711/21/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
662013021656108/22/13 Immunoconjugates with an intracellularly-cleavable linkage
672013020935608/15/13 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
682013021104408/15/13 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
692013017749807/11/13 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
702013017752607/11/13 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
712013017106407/04/13 Anti-cd74 immunoconjugates and methods of use
722013017106507/04/13 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
732013017117607/04/13 Anthracycline-antibody conjugates for cancer therapy
742013016421406/27/13 Antibody-based depletion of antigen-presenting cells and dendritic cells
752013016478306/27/13 Mammalian cell lines for increasing longevity and protein yield from a cell culture
762013015669106/20/13 Antibody therapy
772013014278706/06/13 Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
782013014329606/06/13 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
792013012191305/16/13 Anti-cd19 antibodies
802013012347305/16/13 Bispecific antibody targeting a complement factor or complement regulatory protein
812013009503404/18/13 Anti-cd74 immunoconjugates and methods
822013009045804/11/13 Immunoconjugates with an intracellularly-cleavable linkage
832013007818203/28/13 Structural variants of antibodies for improved therapeutic characteristics
842013007826303/28/13 Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
852013007132003/21/13 Immunotherapy of autoimmune disorders using antibodies which target b-cells
862013007140603/21/13 Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
872013007265903/21/13 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
882013003986102/14/13 Dye conjugated peptides for fluorescent imaging
892013003449202/07/13 Class i anti-cea antibodies and uses thereof
902012032856412/27/12 Camptothecin-binding moiety conjugates
912012032863412/27/12 Immunoconjugates with an intracellularly-cleavable linkage
922012032155312/20/12 Ultrafiltration concentration of allotype selected antibodies for small-volume administration
932012028217811/08/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
942012027610011/01/12 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
952012023095309/13/12 Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
962012021496908/23/12 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
972012019632608/02/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
982012018954207/26/12 Anti-cd19 antibodies
992012018347207/19/12 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1002012018355007/19/12 Therapeutic using a bispecific antibody
1012012014908506/14/12 Fusion proteins containing recombinant cytotoxic rnases
1022012014137206/07/12 Rs7 antibodies
1032012014137506/07/12 Anti-mucin antibodies for early detection and treatment of pancreatic cancer
1042012013492005/31/12 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1052012011455605/10/12 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1062012010723505/03/12 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1072012008829904/12/12 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1082012008261704/05/12 Immunoconjugates with an intracellularly-cleavable linkage
1092012007672703/29/12 In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
1102012006399303/15/12 Therapeutic and diagnostic conjugates for use with multispecific antibodies
1112012003979702/16/12 Antibody therapy
1122012004043102/16/12 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1132012003418502/09/12 Anti-cd20 antibodies and fusion proteins therof and methods of use
1142011031153112/22/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1152011030563112/15/11 Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases
1162011030006612/08/11 Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
1172011029351312/01/11 Immunoconjugates with an intracellularly-cleavable linkage
1182011028691811/24/11 Immunotherapy of autoimmune disorders using antibodies which target b-cells
1192011028080111/17/11 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1202011027470411/10/11 Compositions and methods of use of immunotoxins comprising ranpirnase (rap) show potent cytotoxic activity
1212011025605310/20/11 Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
1222011024384110/06/11 Antibody-based depletion of antigen-presenting cells and dendritic cells
1232011024454610/06/11 Internalizing anti-cd74 antibodies and methods of use
1242011023630409/29/11 Structural variants of antibodies for improved therapeutic characteristics
1252011023640409/29/11 Methods for protein expression in mammalian cells in serum-free medium
1262011022940709/22/11 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1272011022364509/15/11 Multivalent carriers of bi-specific antibodies
1282011019502308/11/11 Internalizing anti-cd74 antibodies and methods of use
1292011018908508/04/11 Antibody therapy
1302011018926808/04/11 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1312011017112607/14/11 Enhanced cytotoxicity of anti-cd74 and anti-hla-dr antibodies with interferon-gamma
1322011016507207/07/11 Detection of early-stage pancreatic adenocarcinoma
1332011016507307/07/11 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
1342011011701005/19/11 Methods and compositions for administering therapeutic and diagnostic agents
1352011011710505/19/11 Method of treating immune disease using b-cell antibodies
1362011011085405/12/11 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1372011007623303/31/11 Delivery system for cytotoxic drugs by bispecific antibody pretargeting
1382011007015503/24/11 Anti-cd74 immunoconjugates and methods
1392011007015603/24/11 Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
1402011006465303/17/11 Class i anti-cea antibodies and uses thereof
1412011005248903/03/11 Anti-cd19 antibodies
1422010031116212/09/10 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1432010028490611/11/10 Internalizing anti-cd74 antibodies and methods of use
1442010027263610/28/10 Anti-cd74 immunoconjugates and methods of use
1452010026649610/21/10 Anti-cd74 immunoconjugates and methods of use
1462010026649710/21/10 Internalizing anti-cd74 antibodies and methods of use
1472010023377909/16/10 Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
1482010022688409/09/10 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
1492010022117509/02/10 Antibody therapy
1502010022117709/02/10 Rs7 antibodies
1512010021666208/26/10 Inhibition of placenta growth factor (plgf) mediated metastasis and/or angiogenesis
1522010020296108/12/10 D-amino acid peptides
1532010019626608/05/10 Humanized anti-hla-dr antibodies
1542010019626708/05/10 Humanized l243 antibodies
1552010019698908/05/10 Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
1562010018964107/29/10 Novel strategies for improved cancer vaccines
1572010015880206/24/10 Chimeric, human and humanized anti-csap monoclonal antibodies
1582010015880306/24/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1592010013662606/03/10 Production and use of novel peptide-based agents for use with bi-specific antibodies
1602010010458904/29/10 Immunoconjugates with an intracellularly-cleavable linkage
1612010007484003/25/10 Anthracycline-antibody conjugates for cancer therapy
1622010006813603/18/10 Anti-cd19 antibodies
1632010004054102/18/10 Structural variants of antibodies for improved therapeutic characteristics
1642010003473802/11/10 Structural variants of antibodies for improved therapeutic characteristics
1652010001504601/21/10 Camptothecin-binding moiety conjugates
1662010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
1672010000885501/14/10 Production and use of novel peptide-based agents with bispecific antibodies
1682010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
1692009030458012/10/09 Anti-pancreatic cancer antibodies
1702009029903312/03/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1712009029109311/26/09 Immunoconjugates with an intracellularly-cleavable linkage
1722009028575211/19/09 Immunotherapy of b cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
1732009027464911/05/09 Bispecific antibody point mutations for enhancing rate of clearance
1742009025273110/08/09 Multivalent carriers of bi-specific antibodies
1752009025317910/08/09 Mammalian cell lines for increasing longevity and protein yield from a cell culture
1762009024613010/01/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1772009024613110/01/09 Production and use of novel peptide-based agents for use with bi-specific antibodies
1782009024621410/01/09 Fusion proteins containing recombinant cytotoxic rnases
1792009023875709/24/09 Methods and compositions for administering therapeutic and diagnostic agents
1802009024003709/24/09 Humanized antibodies and methods of humanizing antibodies
1812009018597407/23/09 Chimeric, human and humanized anti-granulocyte antibodies and methods of use
1822009015516606/18/09 Methods and compositions for f-18 labeling of proteins, peptides and other molecules
1832009015525306/18/09 Anti-cd20 antibodies and fusion proteins therof and methods of use
1842009011114304/30/09 Methods and compositions for mammalian cell lines for transfection and protein expression in serum-free medium
1852009009259804/09/09 Antibody therapy
1862010001504801/21/10 Internalizing anti-cd74 antibodies and methods of use
1872010000885801/14/10 Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunomedics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunomedics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE